|

neoadjuvant immunotherapy Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 3: 1

Top Sponsors

  • Peking University Cancer Hospital & Institute1
  • Fudan University1

Indications

  • Lung Cancer2
  • Cancer2
  • Resectable Stage II-IIIa NSCLC1
  • Lung Surgery1
  • Neoadjuvant Immunotherapy1

Other2 trials

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
Phase 3
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.